1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 153,00 | 159,00 | 16:53 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12:06 | Belite Bio, Inc: Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update | 28 | GlobeNewswire (Europe) | Following positive topline results from the pivotal, global Phase 3 DRAGON trial of tinlarebant in adolescents with Stargardt disease type 1 (STGD1), the Company is on track to submit a New Drug Application... ► Artikel lesen | |
| BELITE BIO Aktie jetzt für 0€ handeln | |||||
| Fr | Exploring Belite Bio's Earnings Expectations | 1 | Benzinga.com | ||
| 30.01. | BELITE BIO, INC - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 28.01. | H.C. Wainwright reiterates Buy rating on Belite Bio stock with $185 target | 2 | Investing.com | ||
| 27.01. | Belite Bio completes enrollment in phase 2/3 STGD1 drug trial | 2 | Investing.com | ||
| 27.01. | BELITE BIO, INC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 26.01. | BofA Securities initiates coverage on Belite Bio stock with Buy rating | 4 | Investing.com | ||
| 16.01. | Cantor Fitzgerald reiterates Overweight rating on Belite Bio stock | 1 | Investing.com | ||
| 06.01. | Morgan Stanley initiates Belite Bio stock with Overweight rating, $191 target | 2 | Investing.com | ||
| 03.12.25 | Belite Bio stock price target raised to $187 from $132 at Benchmark | 3 | Investing.com | ||
| 02.12.25 | Mizuho upgrades Belite Bio stock to Outperform on positive trial data | 1 | Investing.com | ||
| 02.12.25 | Mizuho stuft Belite Bio nach positiven Studiendaten auf 'Outperform' hoch | 10 | Investing.com Deutsch | ||
| 02.12.25 | Belite Bio prices 2.27M ADSs at $154.00 to raise $350M in public offering | 2 | Seeking Alpha | ||
| 02.12.25 | Belite Bio prices public offering of ADSs at $154 each | 1 | Investing.com | ||
| 02.12.25 | Belite Bio, Inc: Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares | 1 | GlobeNewswire (USA) | ||
| 02.12.25 | Why Belite Bio Stock Soared on Monday | 1 | The Motley Fool | ||
| 01.12.25 | Belite Bio kündigt Kapitalerhöhung an - Aktie gibt nach | 2 | Investing.com Deutsch | ||
| 01.12.25 | Belite Bio launches public offering of American Depositary Shares | 1 | Investing.com | ||
| 01.12.25 | Belite Bio announces proposed underwritten public offering of ADSs | 1 | Seeking Alpha | ||
| 01.12.25 | Belite Bio, Inc: Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares | 1 | GlobeNewswire (USA) |
1 2 3 Weiter >>
54 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,720 | -2,36 % | Evotec Aktie vor dem Durchbruch? Diesmal ist etwas anders... | Die Evotec Aktie hat zuletzt ein wichtiges Muster bestätigt: Wiederholt scheiterte die Biotech-Aktie aus Hamburg mit Breakversuchen an der 200-Tage-Linie. Nach mehr oder weniger starken Ausbrüchen hierüber... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 20,010 | 0,00 % | Palatin Technologies, Inc.: Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Advancing differentiated MC4R-based obesity programs into clinical development
Melanocortin-based obesity therapies targeting rare MC4R pathway disorders with... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,350 | -5,07 % | Weekly Buzz: ATYR To Meet With FDA, SGMO Aces Fabry Study, AQST's Anaphylm Gets Rejected | PETAH TIKVA (dpa-AFX) - This week's biotech landscape witnessed key FDA meetings being scheduled, IND clearances, complete response letters, sale of oncology assets and clinical trial data readouts... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,470 | -0,73 % | Viking Therapeutics: The High-Stakes Weight Loss Contender | ||
| ABIVAX | 98,70 | -3,99 % | 2 Reasons Abivax Stock Could 10X by 2036 | ||
| GERON | 1,363 | -3,91 % | Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Achieved $48 million and $184 million in RYTELO (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025, within... ► Artikel lesen | |
| GALAPAGOS NV | 28,520 | 0,00 % | Galapagos NV: Galapagos Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update | Strategic reset positions Galapagos for long-term value creation Robust 2025 year-end cash and financial investments of €3.0 billion and ongoing collaboration with Gilead enable flexibility to execute... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 3,290 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies | FLORHAM PARK, N.J. and LANSING, Mich., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,496 | -8,67 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update | Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:• Robust ORR of 72.2% (vs 43.2% with combined SoC of... ► Artikel lesen | |
| ARGENX | 653,20 | 0,00 % | BERNSTEIN RESEARCH stuft Argenx auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat die Einstufung für Argenx nach Zahlen zum vierten Quartal 2025 mit einem Kursziel von 875 Euro auf "Outperform" belassen. Fortschritte... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,650 | -2,91 % | Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) | New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM-304 Anticipated in 2026 Updated Phase 1/2 Data and Next... ► Artikel lesen | |
| CYTOKINETICS | 53,00 | 0,00 % | Cytokinetics, Incorporated: Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update | MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 8,174 | +7,98 % | Ocular Therapeutix, Inc. (OCUL): A Bull Case Theory | ||
| CYTOMX THERAPEUTICS | 4,320 | -3,83 % | SD-Tipp CytomX: Was tun nach +1.438% in 10 Monaten? | Unsere Aktien-Empfehlung CytomX Therapeutics erlebt derzeit einen außergewöhnlich starken Kursverlauf. Innerhalb kurzer Zeit hat sich das Papier von einem lange übersehenen Small-Cap-Titel zu einem... ► Artikel lesen | |
| PALISADE BIO | 1,760 | -0,85 % | Palisade Bio, Inc.: Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026 | Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and early clinical response within seven days Encouraging safety... ► Artikel lesen |
BELITE BIO INC ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,25 % bei einem Aktienkurs von 158,00 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BELITE BIO INC ADR finden Sie auf Wallstreet Online.